Cytel
Success
You have successfully submitted your enquiry. Someone from our company will respond ASAP
Cytel
White Papers
A game-changer for clinical trial design
Cytel, a leading provider of cutting-edge analytical solutions, quantitative methods, and innovative statistical software for the life sciences industry, has just unveiled an innovative platform that represents a significant advancement in the field of clinical trial design and simulation: East Horizon™. Building on more than 30 years of experience, Cytel has developed a cloud-native, intuitive platform that promises to significantly accelerate the drug development process, making clinical trials more efficient, cost-effective, and reliable. Clinical Trials Insight hears from Kevin Trimm, chief product officer and Aniruddha Deshmukh, VP of Software Engineering at Cytel to find out more.
Press Releases
Cytel Launches East Horizon™ Platform: Advancing the Science of Adaptive Clinical Trial Design and Simulation
New platform integrates East® software’s established adaptive design workflows with cutting-edge cloud computing simulation and advanced design capabilities for enhanced clinical development.
Cytel Acquires stève consultants to Further Expand Real-World Analytics
Cytel Inc., provider of quantitative insights and health data analytics to leaders in life sciences, has acquired stève consultants, specialists in market access, real-world evidence (RWE), and health economics and outcomes research (HEOR). The acquisition further expands Cytel’s real-world & advanced analytics (RWAA) capabilities, giving sponsors an expanded global offering, with access to additional specialists and localized expertise. This acquisition continues the company’s growth in key European markets, following the recent acquisition of Nordic regulatory affairs and RWE experts SDS Life Science. Cytel now stands as one of the largest global providers of HEOR, RWE, global value strategy and market access consulting.
Cytel Continues Expansion of Market Access and Medical Communication Capabilities with the Acquisition of co.faktor
Cytel Inc., provider of quantitative insights and health data analytics to leaders in the life sciences, has acquired the Berlin-based company co.faktor GmbH with its dedicated healthcare consultancy services co.value® (market access), co.medical® (medical communications), and co.patient® (patient relations) concentrations. As a result, Cytel’s services for biopharma commercialization will gain new and complementary specialist consultancy capabilities and localized expertise for successful market access in Germany, a first wave launch country.